Radiology最新文献

筛选
英文 中文
Long-Term Comparison of US-guided Microwave Ablation Combined with Ethanol Injection versus Surgery for Nodular Retrosternal Goiter. 微波消融联合乙醇注射与手术治疗结节性胸骨后甲状腺肿的长期比较。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.253228
Ying-Ying Li, Ming-Bo Zhang, Lin Yan, Jing Xiao, Xin-Yang Li, Zhen Yang, Yu-Kun Luo
{"title":"Long-Term Comparison of US-guided Microwave Ablation Combined with Ethanol Injection versus Surgery for Nodular Retrosternal Goiter.","authors":"Ying-Ying Li, Ming-Bo Zhang, Lin Yan, Jing Xiao, Xin-Yang Li, Zhen Yang, Yu-Kun Luo","doi":"10.1148/radiol.253228","DOIUrl":"https://doi.org/10.1148/radiol.253228","url":null,"abstract":"<p><p>Background Microwave ablation (MWA) combined with ethanol injection (EI) is a minimally invasive technique under preliminary investigation for the treatment of nodular retrosternal goiter (RSG) and has shown promising treatment efficacy. However, a comparative analysis between ablation and surgery is warranted to draw definitive conclusions. Purpose To compare the long-term efficacy and safety of MWA combined with EI versus surgery for patients with nodular RSG. Materials and Methods This retrospective study included patients with nodular RSG treated with MWA combined with EI or surgery between October 2016 and June 2024. Propensity score matching was performed for patients in the ablation and surgery groups, followed by comparisons between the two groups with independent-sample <i>t</i> test, Mann-Whitney <i>U</i> test, χ<sup>2</sup>, or Fisher exact test. Primary outcomes were treatment success, symptom score, and complication rate. Secondary outcomes were cosmetic score, hospitalization, procedure time, estimated blood loss, incision length, and cost. Results This study included 555 patients (mean age ± SD, 51 years ± 14.4; 414 women). After propensity score matching, 224 patients in the ablation group and 224 patients in the surgery group were observed for a median of 48 months (IQR, 24-60 months). No evidence of a difference was observed in the treatment success rates between the ablation and surgery group (98.7% [221 of 224] vs 100% [224 of 224], respectively; <i>P</i> = .08), while both modalities effectively lowered symptom scores from baseline (both <i>P</i> < .001). Compared with surgery, MWA resulted in a lower complication rate (2.2% [five of 224] vs 34.8% [78 of 224], <i>P</i> < .001), shorter posttreatment hospitalization (<i>P</i> < .001), shorter procedure time (<i>P</i> < .001), reduced estimated blood loss (<i>P</i> < .001), shorter incision length (<i>P</i> < .001), lower cost (<i>P</i> < .001), and lower cosmetic score (mean, 1.1 ± 0.3 vs 1.2 ± 0.4; <i>P</i> = .03) at the 12-month follow-up. Conclusion MWA combined with EI was as effective as surgery for nodular RSGs, providing comparable symptom relief while demonstrating fewer complications, offering a safer alternative for eligible patients. © RSNA, 2026 <i>Supplemental material is available for this article.</i></p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e253228"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recognition of Lung Cancer Associated with Cystic Airspaces. 肺癌与囊性空腔的识别。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.262406
Suzanne C Byrne, Mark M Hammer
{"title":"Recognition of Lung Cancer Associated with Cystic Airspaces.","authors":"Suzanne C Byrne, Mark M Hammer","doi":"10.1148/radiol.262406","DOIUrl":"https://doi.org/10.1148/radiol.262406","url":null,"abstract":"","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e262406"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of 7-T and 3-T MRI for the Detection of Multiple Sclerosis Lesions. 7-T与3-T MRI对多发性硬化病变的检测比较。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.260473
Xinyao Liu, De-Cai Tian, Zhe Zhang, Ying Yang, Wanlin Zhu, Ai Guo, Qin Xu, Xiaoyu Shi, Yunyun Duan, Xia Meng, Jing Jing
{"title":"Comparison of 7-T and 3-T MRI for the Detection of Multiple Sclerosis Lesions.","authors":"Xinyao Liu, De-Cai Tian, Zhe Zhang, Ying Yang, Wanlin Zhu, Ai Guo, Qin Xu, Xiaoyu Shi, Yunyun Duan, Xia Meng, Jing Jing","doi":"10.1148/radiol.260473","DOIUrl":"10.1148/radiol.260473","url":null,"abstract":"<p><p>Background MRI is central to multiple sclerosis (MS) diagnosis. Although 7-T MRI improves lesion detection compared with 3-T MRI, systematic head-to-head comparisons across lesion locations and key imaging biomarkers, including the central vein sign (CVS) and paramagnetic rim lesions (PRLs), remain limited; consensus statements call for such studies to better define the clinical value of 7-T MRI. Purpose To systematically compare 7-T and 3-T MRI for detecting MS lesions across characteristic intracranial regions and key imaging biomarkers and to assess the incremental clinical value of 7-T MRI for lesion detection. Materials and Methods Patients with MS from the China National Registry of Neuro-Inflammatory Diseases were prospectively enrolled and underwent same-day 7-T and 3-T MRI examinations (March 2023 to June 2024). Images were anonymized and independently interpreted by two experienced raters in a blinded manner according to standard criteria. Lesion counts were compared with the Wilcoxon signed-rank test; inter- and intrarater reliability were assessed with the intraclass correlation coefficient (ICC) and Cohen κ, respectively. Results Among 30 participants (median age at MRI, 34.5 years [IQR, 30-48.3 years]; 27 female), 7-T MRI depicted more MS lesions overall than 3-T MRI (2268 vs 1779; relative increase, 27.5%; <i>P</i> < .001), with higher detection across cortical (+135.7%), juxtacortical (+26.1%), periventricular (+18.8%), and infratentorial (+33.5%) regions (all <i>P</i> < .001). Moreover, 7-T MRI visualized more CVS-positive lesions (1451 vs 592; +145.1%; <i>P</i> < .001) and more PRLs (634 vs 468; +35.5%; <i>P</i> < .001). The proportion of CVS-positive lesions was higher with 7-T MRI than with 3-T MRI (64.0% vs 33.3%, <i>P</i> < .001), whereas the proportions of PRLs were similar (28.0% vs 26.3%, <i>P</i> = .057). Interrater reliability was excellent (ICC = 0.99). Conclusion Compared with 3-T MRI, 7-T MRI improved MS lesion detection across characteristic intracranial regions and key imaging biomarkers, with a higher proportion of CVS-positive lesions but similar PRL proportions, supporting the clinical value of 7-T MRI. Clinical trial registration no. NCT05154370 © RSNA, 2026 <i>Supplemental material is available for this article.</i></p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e260473"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Better Imaging, Better Outcomes? PROCEM Follows in the Footsteps of COMICE. 更好的成像,更好的结果?程序跟随COMICE的脚步。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.263014
Benoît Mesurolle, Mona El Khoury
{"title":"Better Imaging, Better Outcomes? PROCEM Follows in the Footsteps of COMICE.","authors":"Benoît Mesurolle, Mona El Khoury","doi":"10.1148/radiol.263014","DOIUrl":"https://doi.org/10.1148/radiol.263014","url":null,"abstract":"","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e263014"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma. 89zr -去铁胺- daratumumab用于cd38靶向免疫- pet /CT检测多发性骨髓瘤的2期试验
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.260517
Gary A Ulaner, Russ A Kuker, Benjamin Diamond, James Hoffman, Pooja Motwani, Ben Goldenson, Yaser Homsi, Gary Schiller, Beth Thomsen, Alanna Vossen, Dickran Kazandjian, C Ola Landgren
{"title":"Phase 2 Trial of <sup>89</sup>Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma.","authors":"Gary A Ulaner, Russ A Kuker, Benjamin Diamond, James Hoffman, Pooja Motwani, Ben Goldenson, Yaser Homsi, Gary Schiller, Beth Thomsen, Alanna Vossen, Dickran Kazandjian, C Ola Landgren","doi":"10.1148/radiol.260517","DOIUrl":"10.1148/radiol.260517","url":null,"abstract":"<p><p>Background Multiple myeloma (MM) imaging is currently suboptimal, which may limit patient care. Zirconium 89 (<sup>89</sup>Zr) deferoxamine (DFO)-daratumumab is a novel CD38-targeted immuno-PET tracer. Purpose To compare <sup>89</sup>Zr-DFO-daratumumab PET/CT against standard-of-care fluorine 18 (<sup>18</sup>F) fluorodeoxyglucose (FDG) PET/CT for detection of MM. Materials and Methods Participants with MM were accrued to this prospective phase 2 trial between March 2022 and July 2025. Standard-of-care <sup>18</sup>F-FDG PET/CT and bone marrow biopsy were performed, along with research <sup>89</sup>Zr-DFO-daratumumab PET/CT. If there were discrepant lesions between the two scans, image-guided biopsy was considered as the reference standard. The McNemar test was used to compare disease detection between the two imaging modalities. Results This study included 60 participants (median age, 63 years [IQR, 57-71 years]; 32 women). <sup>89</sup>Zr-DFO-daratumumab PET/CT demonstrated at least one positive lesion in 43% (26 of 60; 95% CI: 31, 57) of participants, and <sup>18</sup>F-FDG PET/CT demonstrated at least one positive lesion in 47% (28 of 60; 95% CI: 33, 60) of participants. While there was no overall difference in disease detection between the two imaging modalities (<i>P</i> = .81), MM was demonstrated only with <sup>89</sup>Zr-DFO-daratumumab PET/CT in 13% (eight of 60) of participants, with subsequent biopsy confirmation of active myeloma. Conclusion In participants with MM, CD38-targeted <sup>89</sup>Zr-DFO-daratumumab immuno-PET helped detect active myeloma in some participants with no signs of disease at <sup>18</sup>F-FDG PET/CT. Clinical trial registration no. NCT04814615 © RSNA, 2026 <i>Supplemental material is available for this article.</i> See also the editorial by Choyke in this issue.</p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e260517"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2026 RSNA Outstanding Researcher. 2026 RSNA杰出研究员。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.269014
Jeffrey S Klein
{"title":"2026 RSNA Outstanding Researcher.","authors":"Jeffrey S Klein","doi":"10.1148/radiol.269014","DOIUrl":"https://doi.org/10.1148/radiol.269014","url":null,"abstract":"","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e269014"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gadolinium Retention in Pediatric Bone: Linear versus Macrocyclic MRI Contrast Agents. 儿童骨钆潴留:线性与大环MRI造影剂。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.252454
Donna R Roberts, Robert Davis Moore, Adam Harrison, Mark J Rosenberg, Anthony M Hlavacek, Minoo N Kavarana, Scott M Bradley, W Clay Davis
{"title":"Gadolinium Retention in Pediatric Bone: Linear versus Macrocyclic MRI Contrast Agents.","authors":"Donna R Roberts, Robert Davis Moore, Adam Harrison, Mark J Rosenberg, Anthony M Hlavacek, Minoo N Kavarana, Scott M Bradley, W Clay Davis","doi":"10.1148/radiol.252454","DOIUrl":"10.1148/radiol.252454","url":null,"abstract":"<p><p>Background Gadolinium retention in bone after gadolinium-based contrast agent (GBCA) exposure is documented in adults but unquantified in children, who may have higher cumulative doses from early imaging. Purpose To quantify and compare residual gadolinium in pediatric bone tissue after macrocyclic and linear GBCA exposure. Materials and Methods In this prospective pilot study, individuals under 18 years of age scheduled for median sternotomy who had undergone clinically indicated GBCA-enhanced or unenhanced MRI were included between January 2018 and August 2024 at a single academic medical center and categorized into three groups: linear GBCA exposed (gadobenate), macrocyclic GBCA exposed (gadoterate), and control (no GBCA exposure). Bone samples were obtained during surgery and analyzed for gadolinium concentration (micrograms of gadolinium per gram of bone tissue). Linear regression modeling was used to analyze the impact of GBCA exposure on bone gadolinium concentration. Results A total of 29 individuals were included: nine exposed to linear GBCA (median age, 12.0 years [IQR, 4.0-14.0 years]; five male individuals), 11 exposed to macrocyclic GBCA (median age, 13.0 years [IQR, 3.3-14.8 years]; eight male individuals), and nine control individuals (median age, 1.8 years [IQR, 0.5-6.3 years]; seven male individuals). Gadolinium was detected in bone tissue in all groups. Median bone gadolinium concentrations were 0.001 μg/g (IQR, 0.0007-0.0015 μg/g) with no GBCA exposure, 0.007 μg/g (IQR, 0.004-0.011 μg/g) with gadoterate exposure, and 0.141 μg/g (IQR, 0.079-0.374 μg/g) with gadobenate exposure. GBCA exposure was associated with gadolinium concentration (adjusted <i>R</i><sup>2</sup> = 0.77; <i>P</i> < .001). Gadobenate exposure was associated with higher gadolinium concentrations than no GBCA exposure (lnβ [log-transformed regression coefficient] = 4.9 [95% CI: 3.7, 5.9]; fold change, 129.8; <i>P</i> < .001) and gadoterate exposure (lnβ = 2.8 [95% CI: 1.6, 3.8]; fold change, 16.0; <i>P</i> < .001). Gadoterate exposure was also associated with higher gadolinium concentrations than no GBCA exposure (lnβ = 2.1 [95% CI: 1.5, 2.7]; fold change, 8.1; <i>P</i> < .001). Conclusion Exposure to the linear agent gadobenate at MRI was associated with higher gadolinium concentrations in bone tissue than no GBCA exposure or exposure to the macrocyclic agent gadoterate; trace gadolinium in the bone tissue of controls may reflect environmental exposure. Clinical trial registration no. NCT03337594 © RSNA, 2026 <i>Supplemental material is available for this article.</i></p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e252454"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glandular Tissue Component at Preoperative Breast US and Recurrence Risk in Invasive Breast Cancer. 浸润性乳腺癌术前乳腺组织成分与复发风险。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.260681
Tingting Deng, Woo Kyung Moon, Cuiju Yan, Huiling Xiang, Jun Tang, Fei Xu, Myoung-Jin Jang, Eun Kyung Park, Heera Yoen, Meesun Lee, Sung Ui Shin, Eun Jae Lee, Na Hye Han, Kyung-Hun Lee, Hyeong-Gon Moon, Su Min Ha, Xi Lin
{"title":"Glandular Tissue Component at Preoperative Breast US and Recurrence Risk in Invasive Breast Cancer.","authors":"Tingting Deng, Woo Kyung Moon, Cuiju Yan, Huiling Xiang, Jun Tang, Fei Xu, Myoung-Jin Jang, Eun Kyung Park, Heera Yoen, Meesun Lee, Sung Ui Shin, Eun Jae Lee, Na Hye Han, Kyung-Hun Lee, Hyeong-Gon Moon, Su Min Ha, Xi Lin","doi":"10.1148/radiol.260681","DOIUrl":"10.1148/radiol.260681","url":null,"abstract":"<p><p>Background Glandular tissue component (GTC) at breast US is associated with breast cancer risk, but recurrence risk remains unclear. Purpose To evaluate the association between GTC assessed at preoperative breast US and recurrence risk in invasive breast cancer across two tertiary institutions in Korea and China. Materials and Methods This retrospective longitudinal study included consecutive women with invasive breast cancer who underwent surgery between January 2013 and December 2018 in Korea and between January 2013 and December 2019 in China. GTC was qualitatively classified as low (minimal or mild) or high (moderate or marked) on preoperative bilateral US images. GTC was prospectively assessed during routine clinical care at institution A (Korea) and retrospectively assessed using archived images at institution B (China). Competing-risk multivariable Fine-Gray models evaluated GTC as the independent variable for recurrence, with adjustment for clinicopathologic variables. Results Mean age was 52.4 years ± 10.8 (SD) at institution A (<i>n</i> = 5167) and 49.2 years ± 10.1 at institution B (<i>n</i> = 3719). Median interval from surgery to recurrence diagnosis or last follow-up was 6.8 years (IQR, 5.42-8.41 years) at institution A and 8.0 years (IQR, 6.38-9.60 years) at institution B. Ipsilateral or contralateral breast cancer occurred in 145 (2.8%) and 85 patients (2.3%) at institutions A and B, respectively, while regional or distant recurrence occurred in 233 (4.5%) and 520 (14.0%). In multivariable analyses, high GTC was independently associated with increased risk of ipsilateral or contralateral breast cancer at institution A (subdistribution hazard ratio [HR], 1.93; <i>P</i> < .001) and institution B (HR, 2.02; <i>P</i> = .002). There was no evidence of an association between GTC and regional or distant recurrence at either institution A (HR, 0.89; <i>P</i> = .46) or institution B (HR, 1.20; <i>P</i> = .06). Conclusion High GTC at preoperative breast US was independently associated with an increased risk of ipsilateral or contralateral breast cancer after invasive breast cancer treatment, consistently across both institutions. © RSNA, 2026 <i>Supplemental material is available for this article.</i></p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e260681"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149380521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting Lymph Node Metastasis in Part-Solid Lung Adenocarcinomas with a Maximum Solid Portion Diameter of 30.0 mm. 预测最大实性部分直径为30.0 mm的部分实性肺腺癌淋巴结转移。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.261341
Xinchun Li, Jinyang Ma, Weicong Chen, Bohang Cui, Hengrui Liang, Dongmei Jiang, Tao Ye, Tao Chen, Yinbo Gong, Shixin Chen, Wang Liu, Qi Wan, Yeqing Zhu
{"title":"Predicting Lymph Node Metastasis in Part-Solid Lung Adenocarcinomas with a Maximum Solid Portion Diameter of 30.0 mm.","authors":"Xinchun Li, Jinyang Ma, Weicong Chen, Bohang Cui, Hengrui Liang, Dongmei Jiang, Tao Ye, Tao Chen, Yinbo Gong, Shixin Chen, Wang Liu, Qi Wan, Yeqing Zhu","doi":"10.1148/radiol.261341","DOIUrl":"https://doi.org/10.1148/radiol.261341","url":null,"abstract":"<p><p>Background The incidence of lymph node (LN) metastasis in patients with part-solid nodules (PSNs) is known to be low, which makes the intraoperative evaluation of LNs a controversial issue. Purpose To investigate the incidence of LN metastasis and explore clinical-radiologic predicting factors for LN metastasis in PSN lung adenocarcinomas with a solid portion diameter of 30.0 mm or less in a large surgical study sample. Materials and Methods This retrospective study included patients with part-solid lung adenocarcinomas with solid portion diameters of 30.0 mm or less on preoperative CT images from July 2023 to December 2024. For each PSN, overall tumor size, solid portion diameter, consolidation-to-tumor ratio (CTR), location, margin, shape, spiculation, lobulation, pleural retraction, bubble-like lucency, and air bronchogram were independently evaluated by two chest radiologists blinded to clinical information and pathology results. Univariable and multivariable logistic regression analyses were performed. Diagnostic performance was evaluated using receiver operating characteristic curve, calibration, and decision curve analysis. Results This study included 1444 patients (median age, 59 years; IQR, 51-67 years; 931 women). The frequency of LN metastasis was 4.7% (68 of 1444 patients). None of the 115 patients with a CTR of 0.25 or less had LN metastasis (N1: 0 of 115; N2: 0 of 115). Rarely (0.2%, one of 552), LN metastasis was found in patients with a solid portion diameter of 6.0 mm or less. Solid portion diameter was the only independent predictor of LN metastasis (odds ratio, 1.25; 95% CI: 1.20, 1.31) in multivariable analysis and showed a superior diagnostic performance compared with CTR (area under the receiver operating characteristic curve, 0.86 [95% CI: 0.82, 0.90] vs 0.75 [95% CI: 0.68, 0.80]; <i>P</i> < .001), along with better calibration (Brier score, 0.039 vs 0.044) and greater net benefit. The clinical actionable cutoff for solid portion diameter was 7.3 mm (sensitivity, 95.6%; specificity, 49.6%). Conclusion Solid portion diameter had a superior diagnostic performance compared with CTR in predicting LN metastasis in patients with part-solid lung adenocarcinomas of solid portion diameter of 30.0 mm or less at CT. © RSNA, 2026 <i>Supplemental material is available for this article.</i></p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e261341"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions (PROCEM): A Randomized Controlled Trial. 术前增强乳房造影在乳腺恶性病变分期中的附加价值(PROCEM):一项随机对照试验。
IF 17.6 1区 医学
Radiology Pub Date : 2026-11-01 DOI: 10.1148/radiol.260857
Anna Gardfjell, Lisa Rydén, Emma Niméus, Sophia Zackrisson, Kristina Åhsberg
{"title":"Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions (PROCEM): A Randomized Controlled Trial.","authors":"Anna Gardfjell, Lisa Rydén, Emma Niméus, Sophia Zackrisson, Kristina Åhsberg","doi":"10.1148/radiol.260857","DOIUrl":"10.1148/radiol.260857","url":null,"abstract":"<p><p>Background Contrast-enhanced mammography (CEM) is increasingly used in breast cancer diagnostics; however, randomized trials assessing the added value of CEM in preoperative staging of breast cancer beyond digital mammography, digital breast tomosynthesis, and US are lacking. Purpose To assess the added value of CEM for preoperative breast cancer staging in a randomized controlled trial. Materials and Methods This prospective randomized controlled trial (Added Value of Preoperative Contrast Enhanced Mammography in Staging of Malignant Breast Lesions) enrolled women diagnosed with early-stage breast cancer eligible for primary surgery at two breast centers in Sweden. Participants were randomized 1:1 to preoperative CEM or control from November 2020 through April 2024. The primary outcome was a 10% change in treatment due to preoperative CEM findings. Secondary outcomes included differences in reoperation and mastectomy rates between groups and accuracy of malignant extent estimation with CEM, mammography/tomosynthesis, and US using histopathologic extent as the reference, assessed with Bland-Altman statistics and concordance analysis. Subgroup analyses were performed according to menopausal status, breast density, histopathologic type of cancer, lesion size, and presence of microcalcifications at baseline imaging. Results In total, 415 participants (median age, 66 years; IQR, 56-73 years) completed the trial: 202 in the CEM group and 213 in the control group. Treatment was changed in 17 of 202 participants (8.4%; 95% CI: 5.3, 13.1) based on CEM findings. No evidence of differences was observed between the CEM and control groups with regard to mastectomy (17% [35 of 202] vs 18% [39 of 213]; <i>P</i> = .78) or reoperation (7.9% [16 of 202] vs 10% [22 of 213]; <i>P</i> = .39) rates. CEM showed the closest agreement with histopathologic malignant extent (bias, 3.5 mm), outperforming mammography and/or tomosynthesis (4.8 mm) and US (10.7 mm) overall and in nine of 10 predefined subgroups, except for ductal carcinoma in situ. Conclusion This trial did not meet its primary end point of a 10% treatment change; however, preoperative CEM improved malignant extent estimation. ClinicalTrials.gov: NCT04437602 © The Author(s) 2026. Published by the Radiological Society of North America under a CC BY 4.0 license. <i>Supplemental material is available for this article.</i> See also the editorial by Mesurolle and El Khoury in this issue.</p>","PeriodicalId":20896,"journal":{"name":"Radiology","volume":"321 2","pages":"e260857"},"PeriodicalIF":17.6,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149324430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书